Solid lipid nanoparticles carrying chemotherapeutic drug across the blood-brain barrier through insulin receptor-mediated pathway

Journal of Drug Targeting

Volumn 21, Issue 8, 2013, Pages 730-738

  Kuo, Yung Chih ^a   Shih Huang, Chun Yuan ^a  

^a NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

Author keywords

83 14 monoclonal antibody; Blood brain barrier; Carmustine; Insulin receptor; Solid lipid nanoparticle

Indexed keywords

CARMUSTINE; INSULIN RECEPTOR; MONOCLONAL ANTIBODY; SOLID LIPID NANOPARTICLE;

ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; CELL VIABILITY; CONTROLLED STUDY; CROSS LINKING; CYTOPATHOGENIC EFFECT; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG STRUCTURE; DRUG TRANSPORT; ENDOCYTOSIS; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MEMBRANE TRANSPORT; MICROVASCULAR ENDOTHELIAL CELL; MOLECULAR INTERACTION; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PARTICLE SIZE; PHAGOCYTOSIS; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN; CARMUSTINE; CELL LINE; CELL SURVIVAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; ENDOTHELIAL CELLS; HUMANS; MICE; NANOPARTICLES; PARTICLE SIZE; PERMEABILITY; RECEPTOR, INSULIN;

EID: 84883217556     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2013.812094     Document Type: Article

References (36)

1. CBTRUS, Statistical report: primary brain tumors in the United States, 1998-2002, Chicago: Central Brain Tumor Registry of the United States (CBTRUS); 2006.
2. Argyriou AA, Antonacopoulou A, Iconomou G, Kalofonos HP. Treatment options for malignant gliomas, emphasizing towards new molecularly targeted therapies. Crit Rev Oncol Hematol 2009;69: 199-210.
3. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005;2: 3-14. (Pubitemid 40128022)
4. Pan W, Kastin AJ. Adipokines and the blood-brain barrier. Peptides 2007;28: 1317-30. (Pubitemid 46843398)
5. See SJ, Gilbert MR. Anaplastic astrocytoma: diagnosis, prognosis, and management. Semin Oncol 2004;31: 618-34. (Pubitemid 39389013)
6. Bredel M. Anticancer drug resistance in primary human brain tumors. Brain Res Rev 2001;35: 161-204. (Pubitemid 32411471)
7. Jones AR, Shusta EV. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm Res 2007;24: 1759-71. (Pubitemid 47206625)
8. Mehnert W, Mader K. Solid lipid nanoparticles production, characterization and applications. Adv Drug Deliv Rev 2001;47: 165-96. (Pubitemid 32324113)
9. Miglietta A, Cavalli R, Bocca C, et al. Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int J Pharm 2000;210: 61-7. (Pubitemid 32332642)
10. Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004;56: 1257-72. (Pubitemid 38510473)
11. Cruz T, Gaspar R, Donato A, Lopes C. Interaction between polyalkylcyanoacrylate nanoparticles and peritoneal macrophages: MTT metabolism, NBT reduction, and NO production. Pharm Res 1997;14: 73-9. (Pubitemid 27113318)
12. Kawai Y, Takasuka N, Inoue K, et al. Ornithine-containing lipids stimulate CD14-dependent TNF-alpha production from murine macrophage-like J774.1 and RAW 264.7 cells. Fems Immunol Med Mic 2000;28: 197-203. (Pubitemid 32939401)
13. Kuo YC, Lu CH. Effect of human astrocytes on the characteristics of human brain-microvascular endothelial cells in the blood-brain barrier. Colloids Surf B 2011;86: 225-31.
14. Shi LJ, Li Z, Yu L, et al. Effects of surfactants and lipids on the preparation of solid lipid nanoparticles using double emulsion method. J Disper Sci Technol 2011;32: 254-9.
15. Aquilano D, Cavalli R, Gasco MR. Solid lipospheres obtained from hot microemulsions in the presence of different concentrations of cosurfactant: the crystallization of stearic acid polymorphs. Thermochimi Acta 1993;230: 29-37.
16. Boltri L, Canal T, Esposito P. Relevant factors affecting the formation and growth of lipid nanospheres suspensions. Eur J Pharm Biopharm 1995;41: 70-5.
17. Hac-Wydro K, Wydro P. The influence of fatty acids on model cholesterol/phospholipid membranes. Chem Phys Lipids 2007;150: 66-81. (Pubitemid 47538550)
18. Catelas I, Petit A, Marchand R, et al. Cytotoxicity and macrophage cytokine release induced by ceramic and polyethylene particles in vitro. J Bone Joint Surg 1999;81-B: 516-21. (Pubitemid 29245912)
19. Goodman CM, McCusker CD, Yilmaz T, Rotello VM. Toxicity of gold nanoparticles functionalized with cationic and anionic side chains. Bioconjug Chem 2004;15: 897-900. (Pubitemid 38981966)
20. Jones CF, Grainger DW. In vitro assessments of nanomaterial toxicity. Adv Drug Deliv Rev 2009;61: 438-56.
21. Kim SB, Ozawa T, Tao H, Umezawa Y. A proinflammatory cytokine sensor cell for assaying inflammatory activities of nanoparticles. Anal Biochem 2007;362: 148-50. (Pubitemid 46198793)
22. Vauthier C, Dubernet C, Fattal E, Patrick C. Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Deliv Rev 2003;55: 519-48. (Pubitemid 36423302)
23. Kabanov AV, Batrakova EV, Alakhov VY. Pluronic- block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev 2002;54: 759-79.
24. Gaillard PJ, de Boer AG. Relationship between permeability status of the blood-brain barrier and in vitro permeability coefficient of a drug. Eur J Pharm Sci 2000;12: 95-102.
25. Kuo YC, Su FL. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate- sulfopropylmethacrylate, and solid lipid nanoparticles. Int J Pharm 2007;340: 143-52.
26. Abbott NJ. Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat 2002;200: 629-38. (Pubitemid 34823054)
27. Flecher NF, Brayden DJ, Brankin B, et al. Growth and characterisation of a cell culture model of the feline blood-brain barrier. Vet Immunol Immunopathol 2006;109: 233-44. (Pubitemid 43042383)
28. Kuo YC, Kuo CY. Electromagnetic interference in the permeability of saquinavir across the blood-brain barrier using nanoparticulate carriers. Int J Pharm 2008;351: 271-81.
29. Alyaudtin R, Reichel A, Lobenberg R, et al. Interaction of poly (butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro. J Drug Target 2001;9: 209-21. (Pubitemid 32776368)
30. Dehouck B, Fenart L, Dehouck M, et al. A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J Cell Biol 1997;138: 877-89. (Pubitemid 27365049)
31. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001;47: 65-81. (Pubitemid 32209233)
32. Kreuter J, Shamenkov D, Petrov V, et al. Apoliporotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target 2002;10: 317-25. (Pubitemid 34746313)
33. Kreuter J. Application of nanoparticles for the delivery of drugs to the brain. Int Congr Ser 2005;1277: 85-94. (Pubitemid 43693337)
34. Kuo YC, Chen HH. Effect of electromagnetic field on endocytosis of cationic solid lipid nanoparticles by human brain-microvascular endothelial cells. J Drug Target 2010;18: 447-56.
35. Sun W, Xie C, Wang H, Hu Y. Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain. Biomaterials 2004;25: 3065-71. (Pubitemid 38210199)
36. Weisgraber KH, Innerarity TL, Harder KJ. The receptor-binding domain of human apolipoprotein E monoclonal antibody inhibition of binding. J Biol Chem 1983;258: 12348-54. (Pubitemid 14231159)